× Digital News Videos Opinion Special Reports Lifestyle Central Coast Eastern Nairobi North Eastern Nyanza Rift Valley Western Business News Stocks Financial Standard Africa Asia America Europe Weird News Editorial Commentary Letters Crazy World Features Entertainment Money & Careers Health & Science Sci & Tech Home & Away Generation Next Cartoon Education Pointblank Environment Travel & Destination Columns Kipkoech Tanui uReport Kiambu Murang'a Nyandarua Kirinyaga Nyeri Baringo Bomet Elgeyo Kajiado Kericho Laikipia Nakuru Nandi Narok Samburu Trans Nzoia Turkana Mombasa Kwale Kilifi Tanariver Taita Taveta Kakamega Vihiga Bungoma Busia Siaya Kisumu Homabay Migori Kisii Nyamira Nairobi Uasin Gishu West Pokot Sunday Magazine The Hague Trial Kenya @ 50 Education and Training Health and Environment Insurance and Financial Security Housing Current Affairs Humour Makau Mutua David Oginde Clay Muganda Comand Your Morning Mohamed Wehliye Wednesday Life Alexander Chagema Arts & Culture Kamotho Waiganjo Barrack Muluka Xn Iraki Urban Rights - By Steve Ouma Branding Voice KCB Fredrick Ogola Sunday Magazine Wanja Kavengi Njoki Kaigai David Oginde Ken Opalo Daisy Maritim Houghton Irungu Hustle News Group Stages Round of 16 Quarter Finals Semi Finals Finals Third Place play-offs Opinion Dr Pesa Podcasts Round Table Sepetuko Eve Woman Ramadhan Special Fact Check Correction Explainers The Standard Insider Blog E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise VAS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS

Lilly says antibody drug cuts hospitalisation among moderate Covid-19 patients

By Reuters | September 16th 2020 at 04:55:28 GMT +0300

Eli Lilly and Co said on Wednesday interim trial data showed its experimental antibody treatment reduced the need for hospitalization and emergency room visits for patients with moderate Covid-19.

Lilly’s mid-stage study tested three different doses of LY-CoV555, an antibody treatment designed to recognize and lock onto the novel coronavirus, thus preventing the infection from spreading.

Analysts expect antibody treatments could help some patients, as broad distribution of coronavirus vaccine candidates is expected to be lengthy.

Many companies including Regeneron Pharmaceuticals Inc and Vir Biotechnology are also testing Covid-19.

Of the total 302 patients treated with three different doses of LY-CoV555, five of them, or 1.7%, had to be admitted to a hospital or visited a hospital emergency room, compared with 6%, or 9 out of 150 on placebo, Lilly said.

Covid 19 Time Series


Only the middle dose, of 2,800 milligrams, achieved the trial’s main goal of reducing the viral load detected in patients compared to a placebo 11 days after treatment, Lilly said.

No drug-related serious adverse events or trial deaths were reported.

Lilly said it expects to publish the results of the interim analysis in a peer-reviewed journal and discuss appropriate next steps with global regulators.

It said the trial, which is ongoing, has now enrolled 800 patients with mild-to-moderate Covid-19. The study is also testing LY-CoV555 in combination with another antibody treatment, LY-CoV016.

The antibodies, given by intravenous infusion, are also being tested for preventing Covid-19 in residents and staff at long-term care facilities and for treating patients already hospitalized due to Covid-19.

Lilly’s shares rose 1.3% to $152 before the opening bell.




Eli Lilly Covid-19 LY-CoV555
Share this story


Read More